Skip Nav Destination
Issues
1 August 2017
-
Cover Image
Cover Image
The cover shows a section of a primary tumor at diagnosis from a patient with metastatic colon cancer who failed a bevacizumab-containing regimen as first-line treatment. Immunohistochemical staining shows HOXB9 expression in tumor cells. For details, see the article by Carbone and colleagues on page 4312 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Perspectives in Regulatory Science and Policy
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Kenneth C. Anderson; Daniel Auclair; Gary J. Kelloff; Caroline C. Sigman; Hervé Avet-Loiseau; Ann T. Farrell; Nicole J. Gormley; Shaji K. Kumar; Ola Landgren; Nikhil C. Munshi; Michele Cavo; Faith E. Davies; Alessandra Di Bacco; Jennifer S. Dickey; Steven I. Gutman; Howard R. Higley; Mohamad A. Hussein; J. Milburn Jessup; Ilan R. Kirsch; Richard F. Little; Robert D. Loberg; Jens G. Lohr; Lata Mukundan; James L. Omel; Trevor J. Pugh; Gregory H. Reaman; Michael D. Robbins; A. Kate Sasser; Nancy Valente; Elena Zamagni
Statistics in CCR
Molecular Pathways
Review
Cancer Therapy: Clinical
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma
Vivek Subbiah; Christian Meyer; Ralph Zinner; Funda Meric-Bernstam; Marianna L. Zahurak; Ashley O'Connor; Jason Roszik; Kenna Shaw; Joseph A. Ludwig; Razelle Kurzrock; Nilofer A. Azad
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
Bojana Jovanović; Ingrid A. Mayer; Erica L. Mayer; Vandana G. Abramson; Aditya Bardia; Melinda E. Sanders; M. Gabriela Kuba; Monica V. Estrada; J. Scott Beeler; Timothy M. Shaver; Kimberly C. Johnson; Violeta Sanchez; Jennifer M. Rosenbluth; Patrick M. Dillon; Andres Forero-Torres; Jenny C. Chang; Ingrid M. Meszoely; Ana M. Grau; Brian D. Lehmann; Yu Shyr; Quanhu Sheng; Sheau-Chiann Chen; Carlos L. Arteaga; Jennifer A. Pietenpol
A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer
Lee S. Schwartzberg; Denise A. Yardley; Anthony D. Elias; Manish Patel; Patricia LoRusso; Howard A. Burris; Ayca Gucalp; Amy C. Peterson; Martha E. Blaney; Joyce L. Steinberg; Jacqueline A. Gibbons; Tiffany A. Traina
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Cynthia X. Ma; Feng Gao; Jingqin Luo; Donald W. Northfelt; Matthew Goetz; Andres Forero; Jeremy Hoog; Michael Naughton; Foluso Ademuyiwa; Rama Suresh; Karen S. Anderson; Julie Margenthaler; Rebecca Aft; Timothy Hobday; Timothy Moynihan; William Gillanders; Amy Cyr; Timothy J. Eberlein; Tina Hieken; Helen Krontiras; Zhanfang Guo; Michelle V. Lee; Nicholas C. Spies; Zachary L. Skidmore; Obi L. Griffith; Malachi Griffith; Shana Thomas; Caroline Bumb; Kiran Vij; Cynthia Huang Bartlett; Maria Koehler; Hussam Al-Kateb; Souzan Sanati; Matthew J. Ellis
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
George Somlo; Paul H. Frankel; Banu K. Arun; Cynthia X. Ma; Agustin A. Garcia; Tessa Cigler; Leah V. Cream; Harold A. Harvey; Joseph A. Sparano; Rita Nanda; Helen K. Chew; Timothy J. Moynihan; Linda T. Vahdat; Matthew P. Goetz; Jan H. Beumer; Arti Hurria; Joanne Mortimer; Richard Piekarz; Sharon Sand; Josef Herzog; Lily R. Van Tongeren; Katherine V. Ferry-Galow; Alice P. Chen; Christopher Ruel; Edward M. Newman; David R. Gandara; Jeffrey N. Weitzel
Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes
Chen Wang; Sebastian M. Armasu; Kimberly R. Kalli; Matthew J. Maurer; Ethan P. Heinzen; Gary L. Keeney; William A. Cliby; Ann L. Oberg; Scott H. Kaufmann; Ellen L. Goode
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux; Zhongwu Lai; Brian A. Dougherty; Sarah Runswick; Darren R. Hodgson; Kirsten M. Timms; Jerry S. Lanchbury; Stan Kaye; Charlie Gourley; David Bowtell; Elise C. Kohn; Claire Scott; Ursula Matulonis; Tony Panzarella; Katherine Karakasis; Julia V. Burnier; C. Blake Gilks; Mark J. O'Connor; Jane D. Robertson; Jonathan Ledermann; J. Carl Barrett; Tony W. Ho; Amit M. Oza
Author Choice
A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors
Rebecca Kristeleit; Geoffrey I. Shapiro; Howard A. Burris; Amit M. Oza; Patricia LoRusso; Manish R. Patel; Susan M. Domchek; Judith Balmaña; Yvette Drew; Lee-may Chen; Tamar Safra; Ana Montes; Heidi Giordano; Lara Maloney; Sandra Goble; Jeff Isaacson; Jim Xiao; Jen Borrow; Lindsey Rolfe; Ronnie Shapira-Frommer
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
Harry Dolstra; Mieke W.H. Roeven; Jan Spanholtz; Basav N. Hangalapura; Marleen Tordoir; Frans Maas; Marij Leenders; Fenna Bohme; Nina Kok; Carel Trilsbeek; Jos Paardekooper; Anniek B. van der Waart; Peter E. Westerweel; Tjeerd J.F. Snijders; Jan Cornelissen; Gerard Bos; Hans F.M. Pruijt; Aniek O. de Graaf; Bert A. van der Reijden; Joop H. Jansen; Arnold van der Meer; Gerwin Huls; Jeannette Cany; Frank Preijers; Nicole M.A. Blijlevens; Nicolaas M. Schaap
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
Jacob D. Soumerai; Andrew D. Zelenetz; Craig H. Moskowitz; M. Lia Palomba; Paul A. Hamlin, Jr; Ariela Noy; David J. Straus; Alison J. Moskowitz; Anas Younes; Matthew J. Matasar; Steven M. Horwitz; Carol S. Portlock; Jason A. Konner; Mrinal M. Gounder; David M. Hyman; Martin H. Voss; Matthew G. Fury; Devika Gajria; Richard D. Carvajal; Alan L. Ho; Jan H. Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F. Little; Christine Jarjies; Thu O. Dang; Fallon France; Nishant Mishra; John F. Gerecitano
Author Choice
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S. Czuczman; Marek Trněný; Andrew Davies; Simon Rule; Kim M. Linton; Nina Wagner-Johnston; Randy D. Gascoyne; Graham W. Slack; Pierre Brousset; David A. Eberhard; Francisco J. Hernandez-Ilizaliturri; Gilles Salles; Thomas E. Witzig; Pier Luigi Zinzani; George W. Wright; Louis M. Staudt; Yandan Yang; P. Mickey Williams; Chih-Jian Lih; Jacqueline Russo; Anjan Thakurta; Patrick Hagner; Pierre Fustier; Dale Song; Ian D. Lewis
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M. Parseghian; Nila U. Parikh; Ji Yuan Wu; Zhi-Qin Jiang; Laura Henderson; Feng Tian; Brice Pastor; Marc Ychou; Kanwal Raghav; Arvind Dasari; David R. Fogelman; Anastasia D. Katsiampoura; David G. Menter; Robert A. Wolff; Cathy Eng; Michael J. Overman; Alain R. Thierry; Gary E. Gallick; Scott Kopetz
Author Choice
Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act
Kenneth L. Kehl; Cheryl P. Fullmer; Siqing Fu; Goldy C. George; Kenneth R. Hess; Filip Janku; Daniel D. Karp; Shumei Kato; Cynthia K. Kizer; Razelle Kurzrock; Aung Naing; Shubham Pant; Sarina A. Piha-Paul; Vivek Subbiah; Apostolia M. Tsimberidou; David S. Hong
First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors
Mark N. Stein; Joseph R. Bertino; Howard L. Kaufman; Tina Mayer; Rebecca Moss; Ann Silk; Nancy Chan; Jyoti Malhotra; Lorna Rodriguez; Joseph Aisner; Robert D. Aiken; Bruce G. Haffty; Robert S. DiPaola; Tracie Saunders; Andrew Zloza; Sherri Damare; Yasmeen Beckett; Bangning Yu; Saltanat Najmi; Christian Gabel; Siobhan Dickerson; Ling Zheng; Wafik S. El-Deiry; Joshua E. Allen; Martin Stogniew; Wolfgang Oster; Janice M. Mehnert
Personalized Medicine and Imaging
Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort
Anika Hüsing; Renée T. Fortner; Tilman Kühn; Kim Overvad; Anne Tjønneland; Anja Olsen; Marie-Christine Boutron-Ruault; Gianluca Severi; Agnes Fournier; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Philippos Orfanos; Giovanna Masala; Valeria Pala; Rosario Tumino; Francesca Fasanelli; Salvatore Panico; H. Bas Bueno de Mesquita; Petra H. Peeters; Carla H. van Gills; J. Ramón Quirós; Antonio Agudo; Maria-Jose Sánchez; Maria-Dolores Chirlaque; Aurelio Barricarte; Pilar Amiano; Kay-Tee Khaw; Ruth C. Travis; Laure Dossus; Kuanrong Li; Pietro Ferrari; Melissa A. Merritt; Ioanna Tzoulaki; Elio Riboli; Rudolf Kaaks
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee; Anthony F. Shields; Barry A. Siegel; Kathy D. Miller; Ian Krop; Cynthia X. Ma; Patricia M. LoRusso; Pamela N. Munster; Karen Campbell; Daniel F. Gaddy; Shannon C. Leonard; Elena Geretti; Stephanie J. Blocker; Dmitri B. Kirpotin; Victor Moyo; Thomas J. Wickham; Bart S. Hendriks
IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831
Monica M. Reinholz; Beiyun Chen; Amylou C. Dueck; Kathleen Tenner; Karla Ballman; Darren Riehle; Robert B. Jenkins; Xochiquetzal J. Geiger; Ann E. McCullough; Edith A. Perez
Author Choice
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy
Leo Zhang; Krystle Nomie; Hui Zhang; Taylor Bell; Lan Pham; Sabah Kadri; Jeremy Segal; Shaoying Li; Shouhao Zhou; David Santos; Shawana Richard; Shruti Sharma; Wendy Chen; Onyekachukwu Oriabure; Yang Liu; Shengjian Huang; Hui Guo; Zhihong Chen; Wenjing Tao; Carrie Li; Jack Wang; Bingliang Fang; Jacqueline Wang; Lei Li; Maria Badillo; Makhdum Ahmed; Selvi Thirumurthi; Steven Y. Huang; Yiping Shao; Laura Lam; Qing Yi; Y. Lynn Wang; Michael Wang
Author Choice
Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone
M. Reza Abbasi; Fikret Rifatbegovic; Clemens Brunner; Georg Mann; Andrea Ziegler; Ulrike Pötschger; Roman Crazzolara; Marek Ussowicz; Martin Benesch; Georg Ebetsberger-Dachs; Godfrey C.F. Chan; Neil Jones; Ruth Ladenstein; Inge M. Ambros; Peter F. Ambros
Author Choice
Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI
Rafal Panek; Liam Welsh; Lauren C.J. Baker; Maria A. Schmidt; Kee H. Wong; Angela M. Riddell; Dow-Mu Koh; Alex Dunlop; Dualta Mcquaid; James A. d'Arcy; Shreerang A. Bhide; Kevin J. Harrington; Christopher M. Nutting; Georgina Hopkinson; Cheryl Richardson; Carol Box; Suzanne A. Eccles; Martin O. Leach; Simon P. Robinson; Kate L. Newbold
Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non–Small Cell Lung Cancer
A.J. van der Wekken; R. Pelgrim; N. 't Hart; N. Werner; M.F. Mastik; L. Hendriks; E.H.F.M. van der Heijden; M. Looijen-Salamon; A.J. de Langen; J. Staal-van den Brekel; S. Riemersma; B.E. van den Borne; E.J.M. Speel; A-M.C. Dingemans; T.J.N. Hiltermann; A. van den Berg; W. Timens; E. Schuuring; H.J.M. Groen
Author Choice
Radiomics Features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma
Bin Zhang; Jie Tian; Di Dong; Dongsheng Gu; Yuhao Dong; Lu Zhang; Zhouyang Lian; Jing Liu; Xiaoning Luo; Shufang Pei; Xiaokai Mo; Wenhui Huang; Fusheng Ouyang; Baoliang Guo; Long Liang; Wenbo Chen; Changhong Liang; Shuixing Zhang
Cancer Therapy: Preclinical
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors
Harriet M. Kluger; Christopher R. Zito; Gabriela Turcu; Marina K. Baine; Hongyi Zhang; Adebowale Adeniran; Mario Sznol; David L. Rimm; Yuval Kluger; Lieping Chen; Justine V. Cohen; Lucia B. Jilaveanu
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients
Carmine Carbone; Geny Piro; Francesca Simionato; Francesca Ligorio; Chiara Cremolini; Fotios Loupakis; Greta Alì; Daniele Rossini; Valeria Merz; Raffaela Santoro; Camilla Zecchetto; Marco Zanotto; Federica Di Nicolantonio; Alberto Bardelli; Gabriella Fontanini; Giampaolo Tortora; Davide Melisi
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B. Hanker; Joan T. Garrett; Mónica Valeria Estrada; Preston D. Moore; Paula González Ericsson; James P. Koch; Emma Langley; Sharat Singh; Phillip S. Kim; Garrett M. Frampton; Eric Sanford; Philip Owens; Jennifer Becker; M. Reid Groseclose; Stephen Castellino; Heikki Joensuu; Jens Huober; Jan C. Brase; Samira Majjaj; Sylvain Brohée; David Venet; David Brown; José Baselga; Martine Piccart; Christos Sotiriou; Carlos L. Arteaga
Author Choice
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models
Mari I. Suominen; Katja M. Fagerlund; Jukka P. Rissanen; Yvonne M. Konkol; Jukka P. Morko; ZhiQi Peng; Esa J. Alhoniemi; Salla K. Laine; Eva Corey; Dominik Mumberg; Karl Ziegelbauer; Sanna-Maria Käkönen; Jussi M. Halleen; Robert L. Vessella; Arne Scholz
Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
Yasmine Assadipour; Nikolaos Zacharakis; Jessica S. Crystal; Todd D. Prickett; Jared J. Gartner; Robert P.T. Somerville; Hui Xu; Mary A. Black; Li Jia; Harshini Chinnasamy; Isaac Kriley; Lily Lu; John R. Wunderlich; Zhili Zheng; Yong-Chen Lu; Paul F. Robbins; Steven A. Rosenberg; Stephanie L. Goff; Steven A. Feldman
Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro
Sandra Rebouissou; Tiziana La Bella; Samia Rekik; Sandrine Imbeaud; Anna-Line Calatayud; Nataliya Rohr-Udilova; Yoann Martin; Gabrielle Couchy; Paulette Bioulac-Sage; Bettina Grasl-Kraupp; Leanne de Koning; Nathalie Ganne-Carrié; Jean-Charles Nault; Marianne Ziol; Jessica Zucman-Rossi
Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma
Haibo Sun; De-Chen Lin; Qi Cao; Brendan Pang; David D. Gae; Victor Kwan Min Lee; Huey Jin Lim; Ngan Doan; Jonathan W. Said; Sigal Gery; Marilynn Chow; Anand Mayakonda; Charles Forscher; Jeffrey W. Tyner; H. Phillip Koeffler
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Dennis Shin-Shian Hsu; Wei-Lun Hwang; Chiou-Hwa Yuh; Chen-Hsi Chu; Yang-Hui Ho; Pon-Bo Chen; Han-Syuan Lin; Hua-Kuo Lin; Shih-Pei Wu; Chih-Yi Lin; Wen-Hao Hsu; Hsin-Yi Lan; Hsiao-Jung Wang; Shyh-Kuan Tai; Mien-Chie Hung; Muh-Hwa Yang
Biology of Human Tumors
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases
Charlotte K.Y. Ng; Francois-Clement Bidard; Salvatore Piscuoglio; Felipe C. Geyer; Raymond S. Lim; Ino de Bruijn; Ronglai Shen; Fresia Pareja; Samuel H. Berman; Lu Wang; Jean-Yves Pierga; Anne Vincent-Salomon; Agnes Viale; Larry Norton; Brigitte Sigal; Britta Weigelt; Paul Cottu; Jorge S. Reis-Filho
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma
Nicolas A. Giraldo; Etienne Becht; Yann Vano; Florent Petitprez; Laetitia Lacroix; Pierre Validire; Rafael Sanchez-Salas; Alexandre Ingels; Stephane Oudard; Audrey Moatti; Benedicte Buttard; Sarah Bourass; Claire Germain; Xavier Cathelineau; Wolf H. Fridman; Catherine Sautès-Fridman
Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers
Erik S. Knudsen; Paris Vail; Uthra Balaji; Hoai Ngo; Ihab W. Botros; Vladimir Makarov; Nadeem Riaz; Vinod Balachandran; Steven Leach; Debrah M. Thompson; Timothy A. Chan; Agnieszka K. Witkiewicz
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project
Bo Hwa Sohn; Jun-Eul Hwang; Hee-Jin Jang; Hyun-Sung Lee; Sang Cheul Oh; Jae-Jun Shim; Keun-Wook Lee; Eui Hyun Kim; Sun Young Yim; Sang Ho Lee; Jae-Ho Cheong; Woojin Jeong; Jae Yong Cho; Joohee Kim; Jungsoo Chae; Jeeyun Lee; Won Ki Kang; Sung Kim; Sung Hoon Noh; Jaffer A. Ajani; Ju-Seog Lee
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Ombretta Melaiu; Marco Mina; Marco Chierici; Renata Boldrini; Giuseppe Jurman; Paolo Romania; Valerio D'Alicandro; Maria C. Benedetti; Aurora Castellano; Tao Liu; Cesare Furlanello; Franco Locatelli; Doriana Fruci
Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Johanne I. Weberpals; Bryan Lo; Marc M. Duciaume; Johanna N. Spaans; Aisling A. Clancy; Jim Dimitroulakos; Glenwood D. Goss; Harman S. Sekhon
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds